*ncbi.life
			The Human Reference Genome

  Source:		IFNB1


    		interferon beta 1
     
			CCATACCCATGGAGAAAGGACATTC... Show All

			Summary
			This gene encodes a cytokine that belongs
			to the interferon family of signaling proteins,
			which are released as part of the innate
			immune response to pathogens. The protein
			encoded by this gene belongs to the type
			I class of interferons, which are important
			for defense against viral infections. In
			addition, type I interferons are involved
			in cell differentiation and anti-tumor defenses.
			Following secretion in response to a pathogen,
			type I interferons bind a homologous receptor
			complex and induce transcription of genes
			such as those encoding inflammatory cytokines
			and chemokines. Overactivation of type I
			interferon secretion is linked to autoimmune
			diseases. Mice deficient for this gene display
			several phenotypes including defects in
			B cell maturation and increased susceptibility
			to viral infection.

			Location
			Chromosome 9

			MedGen Concepts
			Sting-associated vasculopathy, infantile-onset

			PubMed
			30229541 Pediatric Multiple Sclerosis: an
			Update.

			30217172 Effect of interferon beta-1a
			subcutaneously three times weekly on clinical
			and radiological measures and no evidence of
			disease activity status in patients with
			relapsing-remitting multiple sclerosis at year 1.

			30216756 Peginterferon beta-1a for the
			treatment of relapsing multiple sclerosis: A case
			series.

			30210736 Interferon beta-1b-induced
			thrombotic thrombocytopenic
			purpura-hemolytic uremic syndrome (TTP-HUS)
			in a patient treated for multiple sclerosis: A
			case report.

			30207920 Trial of Fingolimod versus Interferon
			Beta-1a in Pediatric Multiple Sclerosis.

			30206152 Deconvolution of pro- and antiviral
			genomic responses in Zika virus-infected and
			bystander macrophages.

			30195200 Efficacy and safety of monoclonal
			antibody therapies for relapsing remitting
			multiple sclerosis: A network meta-analysis.

			30181778 Long-term outcomes of
			peginterferon beta-1a in multiple sclerosis:
			results from the ADVANCE extension study,
			ATTAIN.

			30171370 A randomized double-blind trial of
			comparative efficacy and safety of Avonex and
			CinnoVex for treatment of relapsing-remitting
			multiple sclerosis.

			30155789 MRI-based prediction of conversion
			from clinically isolated syndrome to clinically
			definite multiple sclerosis using SVM and lesion
			geometry.

			30143019 Sleep quality, daytime sleepiness,
			fatigue, and quality of life in patients with
			multiple sclerosis treated with interferon
			beta-1b: results from a prospective
			observational cohort study.

			30050291 Treatment satisfaction significantly
			improves in patients with multiple sclerosis
			switching from interferon beta therapy to
			peginterferon beta-1a every 2 weeks.

			30036854 Treatment retention on fingolimod
			compared with injectable multiple sclerosis
			therapies in African-American patients: A
			subgroup analysis of a randomized phase 4
			study.

			Clinical Trials
			3679468 Improving Cognition in People With
			Progressive Multiple Sclerosis Using Aerobic
			Exercise and Cognitive Rehabilitation

			3614715 Pharmacokinetics and
			Pharmacodynamics of CinnoVex (Interferon
			Beta-1a) Compared to Avonex (Interferon
			Beta-1a)

			3424733 Evaluating the Use of Prednisone to
			Decrease Pegylated Interferon Beta-1a Side
			Effects

			3408093 Study of Betaferon Adherence in
			Patients With Multiple Sclerosis Treated With
			Interferon Beta-1b

			2845843 MERS-CoV Infection tReated With A
			Combination of Lopinavir /Ritonavir and
			Interferon Beta-1b

			2665221 Single Center, Open Label, Study of
			Preparation H on Erythema in Relapsing MS
			Patients Treated With PLEGRIDY

			2622724 Efficacy and Safety of FP-1201-lyo
			(Interferon Beta-1a) in Patients Having Acute
			Respiratory Distress Syndrome (ARDS)

			2517788 Phase I BP Interferon (IFN) Beta-004

			2515695 Phase I BP Interferon (IFN) Beta-001

			2491684 A Study in Asthma Patients to
			Evaluate Efficacy, Safety and Tolerability of 14
			Days Once Daily Inhaled Interferon Beta-1a
			After the Onset of Symptoms of an Upper
			Respiratory Tract Infection

			2490943 A Pilot Study of Warm and Cold
			Compress to Reduce Injection Site Erythema
			Due to Peginterferon-beta-1a in MS

			2474134 Comparison Study of PF530 and
			Betaferon in Healthy Subjects

			2394782 Observational Study of Rebismart®2.0
			+ MSdialog™ in Subjects With Remitting Multiple
			Sclerosis (ADHERQOL)

			2364986 Immune- and miRNA-response to
			Recombinant Interferon Beta in Healthy
			Volunteers and Patients With Relapsing
			Remitting Multiple Sclerosis

			2236624 Aerobic Exercise and Flu-like
			Symptoms Following Interferon Beta 1a
			Injections in Patients With Multiple Sclerosis?

			2125578 A Multiple Dose Safety Study of
			PEG-IFN in Healthy Volunteers

			2064816 A Study of Rebif® in Subjects With
			Relapsing Multiple Sclerosis

			1978652 Pharmacokinetic Study of
			Peginterferon Beta-1a in Japanese and
			Caucasian Adult Healthy Participants.

			1939002 Characterize Flu-like Symptoms in
			Relapsing Multiple Sclerosis Patients
			Transitioning From Non-Pegylated Interferon
			Beta (IFN-β) Therapies to Peginterferon Beta-1a
			(BIIB017)

			1911767 Biogen Multiple Sclerosis Pregnancy
			Exposure Registry

			1892722 Safety and Efficacy of Fingolimod in
			Pediatric Patients With Multiple Sclerosis

			1795872 Follow-up Study After 11 Years of
			Patients Who Were Included in the BENEFIT
			Trial (304747) With a First Demyelinating Event
			Suggestive of Multiple Sclerosis

			1717664 Proof of Concept Study of RHB-104
			as Add-On Therapy to Interferon Beta-1a in
			Relapsing Remitting Multiple Sclerosis (RRMS)

			1714089 Proof of Concept Study Evaluating
			RNS60 in the Treatment of Relapsing Remitting
			Multiple Sclerosis

			1701856 Natalizumab De-escalation to
			Interferon-beta-1b in Patients With
			Relapsing-remitting Multiple Sclerosis

			1647880 MOdification of VIsual Outcomes
			After Optic Neuritis in CIS or MS by Gilenya
			(MOVING Study)

			1610310 Peginterferon Beta-1a (BIIB017)
			Autoinjector Pharmacokinetic Study in Healthy
			Volunteers

			1500408 Demonstrate the Bioequivalence of
			Interferon Beta-1a (INFB) Manufactured by Two
			Different Processes in Healthy Volunteers

			1412333 A Study of Ocrelizumab in
			Comparison With Interferon Beta-1a (Rebif) in
			Participants With Relapsing Multiple Sclerosis

			1339676 Colecalciferol as an Add-on
			Treatment to Interferon-beta-1b for Treatment
			of Multiple Sclerosis (MS)

			1337427 Using Optical Coherence
			Tomography (OCT) to Evaluate the Efficacy and
			Safety of PEGylated Interferon Beta-1a
			(BIIB017) in Patients With Relapsing Multiple
			Sclerosis

			1333501 Fingolimod Versus Interferon Beta 1b
			in Cognitive Symptoms

			1333358 Evaluating Alemtuzumab as a
			Treatment in Stabilizing Neurocognitive
			Function In Relapsing Remitting Multiple
			Sclerosis Patients

			1332019 Long-Term Safety and Efficacy Study
			of Peginterferon Beta-1a

			1247324 A Study of Ocrelizumab in
			Comparison With Interferon Beta-1a (Rebif) in
			Participants With Relapsing Multiple Sclerosis

			1198132 A Multicentre Study of the Efficacy
			and Safety of Supplementary Treatment With
			Cholecalciferol in Patients With Relapsing
			Multiple Sclerosis Treated With Subcutaneous
			Interferon Beta-1a 44 µg 3 Times Weekly

			1181115 Avonex Safety and Tolerability in
			Chinese Subjects With Relapsing Multiple
			Sclerosis (MS)

			1144052 Natalizumab De-escalation With
			Interferon Beta-1b

			1119781 A Single-Dose,
			Pharmacokinetic/Pharmacodynamic (PK/PD), &
			Safety Study of BIIB017 in Participants With
			Renal Impairment & Healthy Volunteers

			1112345 An Observational Study for the
			Assessment of Compliance and Persistence to
			Rebif® Therapy of Patients With
			Relapsing-remitting Multiple Sclerosis (MS) and
			Evaluation of Potential Factors Influencing
			These Parameters

			1111656 Efficacy, Safety and Tolerability of
			Atorvastatin 40 mg in Patients With
			Relapsing-remitting Multiple Sclerosis Treated
			With Interferon-beta-1b

			1075880 Post-Authorization Observational
			Study to Evaluate Cognition and Fatigue in
			Relapsing-remitting Multiple Sclerosis (RRMS)
			Patients Treated With Rebif®

			1074593 Pharmacokinetics and
			Pharmacodynamics of the Interferon Beta-1a
			Produced by Laboratorio Quimico
			Farmaceutico Bergamo Compared to Interferon
			Beta-1a (Rebif - Merck Serono) in Healthy
			Subjects

			1067573 The Role of Serum leptin Levels in
			Multiple Sclerosis Disease Activity While on
			Interferon Beta 1a (Rebif) Treatment

			942591 Atorvastatin 40 mg in Patients With
			Relapsing-Remitting Multiple Sclerosis Treated
			With Interferon-Beta-1b

			930553 An Extension Protocol for Multiple
			Sclerosis Patients Who Participated in
			Genzyme-Sponsored Studies of Alemtuzumab

			928967 Open, Multicentric, Prospective, Quality
			of Life Study in Multiple Sclerosis Patients

			917839 The Neuroprotective Effect of
			Lamotrigine and Interferon Beta 1a in Patients
			With Relapsing-Remitting Multiple Sclerosis

			914758 Comparison of Campath and Rebif
			Treatment on Cognition in Multiple Sclerosis
			(MS)

			913666 Pharmacodynamic Study to Better
			Understand the Therapeutic Response and
			Immunomodulatory Effects of Avonex in
			Multiple Sclerosis (MS) Patients and Healthy
			Volunteers

			906399 Efficacy and Safety Study of
			Peginterferon Beta-1a in Participants With
			Relapsing Multiple Sclerosis

			883337 A Study Comparing the Effectiveness
			and Safety of Teriflunomide and Interferon
			Beta-1a in Patients With Relapsing Multiple
			Sclerosis

			771043 A Proof-of-Concept Study to Correlate
			Retinal Nerve Fiber Layer Changes in Patients
			With Multiple Sclerosis Treated With
			Natalizumab or Interferon Beta 1-a

			735007 12-week Study to Evaluate RebiSmart™
			Suitability for Self Injection in Relapsing Multiple
			Sclerosis.

			676715 A Study of the Efficacy and Safety of
			Ocrelizumab in Patients With
			Relapsing-Remitting Multiple Sclerosis

			619307 Transition to Rebif New Formulation

			618527 Combination Therapy Using Cellcept
			and Rebif in RRMS

			616434 A Phase 2 Study of Interferon Beta-1a
			(Avonex®) in Ulcerative Colitis

			548405 Comparison of Alemtuzumab and Rebif®
			Efficacy in Multiple Sclerosis, Study Two

			534261 Does Quality of Life Improve in Multiple
			Sclerosis Patients Treated With Interferon
			Beta-1a?

			530348 Comparison of Alemtuzumab and Rebif®
			Efficacy in Multiple Sclerosis, Study One

			501943 Neuroprotection With Riluzole Patients
			With Early Multiple Sclerosis

			501696 A Randomized Placebo-Controlled,
			Crossover-Design Study of the Effects of Low
			Dose Naltrexone

			493116 Is IFN-beta Treatment in MS Useful
			After a Washout Period in Patients With
			Neutralizing Antibodies to Interferon Beta

			493077 Safety of Avonex Treatment in Multiple
			Sclerosis Patients With Neutralizing Antibodies
			to Interferon Beta Therapy

			492765 Simvastatin as an Add-on Treatment
			to Interferon-beta-1a for the Treatment of
			Relapsing-Remitting Multiple Sclerosis

			492466 Investigating if Interferon-Beta Can be
			Used in Patients With MS After They Have
			Developed Neutralizing Antibodies

			464074 Evaluation of Natalizumab for thE Relief
			of MS Associated FatiGue

			459667 BEYOND Follow-up:
			Betaferon®/Betaseron® Efficacy Yielding
			Outcomes of a New Dose

			441103 A Study to Evaluate Rebif® New
			Formulation (Interferon-beta-1a) in Relapsing
			Remitting Multiple Sclerosis

			439257 Costs, Quality of Life and Functional
			Outcomes in Veterans Treated for Multiple
			Sclerosis With Beta-Interferon l-B (Betaseron)

			360906 Omega-3 Fatty Acid Treatment in
			Multiple Sclerosis

			304252 Safety and Efficacy of Treatment With
			Interferon Beta-1a Rebif® in Patients With
			Crohns Disease

			303381 Safety and Efficacy of
			Interferon-Beta-1a (Rebif®) for Treating Subjects
			With Acute Symptoms of Ulcerative Colitis

			298662 Combination Therapy of
			Betaseron-Prograf in Multiple Sclerosis

			292266 A Study of Rebif® Compared With
			Avonex® in the Treatment of Relapsing-remitting
			Multiple Sclerosis (MS)

			249860 A Multicenter Phase 3 Study of
			Interferon-beta-1a for the Treatment of Chronic
			Hepatitis C in Asian Subjects

			246324 Safety and Efficacy Study of
			Doxycycline in Combination With
			Interferon-B-1a to Treat Multiple Sclerosis

			223457 Factors That Influence Compliance
			With Disease-Modifying Therapy in Multiple
			Sclerosis

			185250 Betaferon/ Betaseron (Interferon
			Beta-1b) in Patients With Chronic Viral
			Cardiomyopathy

			151801 Safety and Tolerability of
			Interferon-Beta-1a and Estroprogestins
			Association in MS Patients

			146068 EARLY IFNB-1a and Simvastatin
			Combination Therapy in Clinically Isolated
			Syndrome Suggestive of Multiple Sclerosis

			99502 BEYOND: Betaferon/Betaseron Efficacy
			Yielding Outcomes of a New Dose in Multiple
			Sclerosis (MS) Patients

			99489 Safety and Efficacy of Avonex in
			Subjects With Chronic Inflammatory
			Demyelinating Polyradiculoneuropathy (CIDP)

			97318 Safety Study of Interferon Beta 1a to for
			Acute Stroke

			94172 Atorvastatin (Lipitor) Therapy in Patients
			With Clinically Isolated Syndrome (CIS) at Risk
			for Multiple Sclerosis

			50778 A Phase II Study Comparing Low- and
			High-Dose Alemtuzumab and High-Dose Rebif®
			in Patients With Early, Active
			Relapsing-Remitting Multiple Sclerosis

			1785 Recombinant Human Interferon Beta-1a
			(Avonex) for the Treatment of Patients With
			HTLV-1-Associated Myelopathy (HAM)

     		                         Embed       Tweet       Print